- Home
- SENS vs IKT Comparison
SENS vs IKT Comparison
Compare SENS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENS
- IKT
- Stock Information
- Founded
- SENS 1996
- IKT 2008
- Country
- SENS United States
- IKT United States
- Employees
- SENS N/A
- IKT N/A
- Industry
- SENS Industrial Machinery/Components
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- SENS Industrials
- IKT Health Care
- Exchange
- SENS Nasdaq
- IKT Nasdaq
- Market Cap
- SENS 179.7M
- IKT 159.2M
- IPO Year
- SENS N/A
- IKT 2020
- Fundamental
- Price
- SENS $0.44
- IKT $3.88
- Analyst Decision
- SENS Strong Buy
- IKT Strong Buy
- Analyst Count
- SENS 1
- IKT 2
- Target Price
- SENS $2.00
- IKT $6.50
- AVG Volume (30 Days)
- SENS 11.3M
- IKT 292.3K
- Earning Date
- SENS 11-07-2024
- IKT 11-14-2024
- Dividend Yield
- SENS N/A
- IKT N/A
- EPS Growth
- SENS N/A
- IKT N/A
- EPS
- SENS N/A
- IKT N/A
- Revenue
- SENS $22,205,000.00
- IKT $1.00
- Revenue This Year
- SENS $1.05
- IKT N/A
- Revenue Next Year
- SENS $61.23
- IKT N/A
- P/E Ratio
- SENS N/A
- IKT N/A
- Revenue Growth
- SENS 11.41
- IKT N/A
- 52 Week Low
- SENS $0.25
- IKT $1.12
- 52 Week High
- SENS $0.75
- IKT $4.14
- Technical
- Relative Strength Index (RSI)
- SENS 65.39
- IKT 78.51
- Support Level
- SENS $0.40
- IKT $3.12
- Resistance Level
- SENS $0.53
- IKT $3.61
- Average True Range (ATR)
- SENS 0.05
- IKT 0.39
- MACD
- SENS 0.02
- IKT 0.10
- Stochastic Oscillator
- SENS 60.04
- IKT 84.66
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.